(PLX) Protalix BioTherapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PLX) Protalix BioTherapeutics, Inc. Complete Analysis Pack
See the Bigger Picture
This Protalix BioTherapeutics, Inc. BCG Matrix helps you assess the company’s products or business units across Stars, Cash Cows, Question Marks, and Dogs for strategy, portfolio review, and investment analysis. The content on this page is a real preview/sample of the actual report, so you can see the format and quality before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
Elfabrio (PRX-102), 2023 FDA approval
Elfabrio (PRX-102), approved by the FDA in 2023, is Protalix BioTherapeutics, Inc.’s clearest growth asset at end-2025, now moving from development into commercialization. Fabry disease is a rare, chronic orphan market, and treatment use still depends on launch execution and patient uptake. That makes Elfabrio the company’s best growth lever, even as it still needs sales support.
Chiesi partnership, global Fabry commercialization
Protalix BioTherapeutics, Inc. markets PRX-102, now Elfabrio, through Chiesi, not a solo sales force. That gives the Fabry drug access to Chiesi’s global rare-disease reach and lowers Protalix’s selling costs, which matters in a niche market with roughly 1 in 40,000 male births affected. Launch execution and coverage drive uptake here.
Fabry franchise, 1 approved growth platform
Fabry is Protalix BioTherapeutics, Inc.'s main growth platform: ELFABRIO was approved in the U.S. in 2023 and in the EU in 2024, giving the franchise a newer launch curve than ELELYSO. That keeps it in a high-growth BCG profile, not a mature one. The key watch item is share capture, since Fabry still has room to scale if prescriber uptake keeps building.
ProCellEx platform, 2 commercial biologics
ProCellEx is Protalix BioTherapeutics, Inc.'s core plant-cell expression platform, and by end-2025 it supports 2 commercial biologics: ELELYSO for Gaucher and ELFABRIO for Fabry. That gives the platform value beyond one product, since it already generates approved-market use and de-risks future protein programs. The setup matters because 2 marketed assets make ProCellEx a real growth base, not just an R&D tool.
- 2 commercial biologics on ProCellEx
- Gaucher and Fabry assets
- Platform has multi-product value
- Supports future protein launches
Rare-disease commercial capability, 2 marketed products
By 2025, Protalix BioTherapeutics had 2 marketed rare-disease products: Elelyso and Elfabrio. That gives it a small but real commercial base, which matters for a micro-cap biopharma because it can support cash flow, partner talks, and follow-on R&D. In BCG terms, this is a focused "star" style execution model: low volume, but high strategic value in orphan drugs.
Elelyso has been on the market since 2012, and Elfabrio was approved in 2023, so the base is not just symbolic. The rare-disease setup also helps Protalix keep a clearer path to pricing power and specialty uptake than broad primary-care drugs. The growth case depends on turning this 2-product base into steady revenue and new partner-led launches.
- 2 marketed products by 2025
- Elelyso launched in 2012
- Elfabrio approved in 2023
- Supports funding and partner talks
Elfabrio Drives Protalix’s Two-Drug Commercial Growth Story
Elfabrio is Protalix BioTherapeutics, Inc.'s Star asset: FDA approved in 2023, EU approved in 2024, and still in launch mode in 2025/2026. The rare Fabry market is small but high value, so growth depends on uptake, payer access, and Chiesi-led execution. ProCellEx gives the franchise a 2-product commercial base.
| Item | 2025/2026 |
|---|---|
| Marketed biologics | 2 |
| Elfabrio status | Growth launch |
What is included in the product
Detailed Word Document
Protalix BioTherapeutics’ BCG Matrix maps its drugs by growth and share, showing where to invest, hold, or divest.
Editable Excel File
Quick BCG view of Protalix BioTherapeutics, Inc. to pinpoint pain points and growth bets.
Reference Sources
Provides a traceable source trail for Protalix BioTherapeutics, Inc., boosting credibility and speeding investor due diligence.
Cash Cows
Elelyso (taliglucerase alfa), 2012 launch
Elelyso (taliglucerase alfa) launched in 2012 and has now spent 13+ years on the market, making it Protalix BioTherapeutics, Inc.’s longest-running commercial asset. As an approved Gaucher disease therapy, it fits the classic cash-cow profile: a rare-disease product with steady, mature revenue potential and lower launch risk than newer pipeline assets.
Gaucher disease franchise, established orphan market
Gaucher disease is an established orphan market, affecting about 1 in 40,000 to 60,000 births. That gives Protalix BioTherapeutics, Inc. a known physician and patient base, so it does not need a big new-market buildout.
Commercialization intensity is lower than for launch-stage assets, because the treatment pathway is already familiar. This kind of franchise supports recurring revenue with limited growth spending and steadier cash generation.
Pfizer commercialization channel, 1 major partner
Protalix BioTherapeutics, Inc. uses Pfizer as the single major commercialization partner for Elelyso, which extends market reach far beyond what Protalix could build alone. In BCG terms, that fits a cash cow: a mature product with steady, low-growth partnership income. The model is built for recurring cash, not fast expansion.
Israel and other international sales, recurring base
Elelyso has been sold in Israel and other international markets for years, so it gives Protalix BioTherapeutics, Inc. a recurring revenue base outside the core pipeline. In the latest reported period, this kind of steady, non-explosive sales helped support total revenue and reduce reliance on new launch timing. That durability is why this fits the cash-cow bucket.
- Recurring, market-proven product sales
- Supports revenue stability
- Low growth, but durable cash flow
Approved-product revenue, lower incremental R and D
Elelyso, Protalix BioTherapeutics, Inc.'s approved Gaucher disease therapy, can bring in cash with far less development risk than pipeline assets. Because it is past the clinical-cost peak, incremental R and D per revenue dollar is typically lower, which helps margins. That makes this product line more cash-generative than the pipeline, which still needs heavy spend and carries binary trial risk.
- Approved product, lower risk.
- Elelyso is past peak R and D.
- More revenue can become free cash.
Elelyso: Protalix’s Steady Cash Cow in a Rare Disease Market
Elelyso, launched in 2012, is Protalix BioTherapeutics, Inc.’s most mature asset and a classic cash cow.
Its Gaucher market is known and rare, about 1 in 40,000 to 60,000 births, so sales need little new-market spend.
Pfizer reach and lower R and D burden make cash flow steadier than the pipeline.
| Metric | Data |
|---|---|
| Elelyso launch | 2012 |
| Gaucher incidence | 1 in 40,000 to 60,000 births |
Preview the Actual Deliverable
Protalix BioTherapeutics, Inc. Reference Sources
The Protalix BioTherapeutics, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No placeholders, no demo pages—just the complete, professionally formatted report.
Once purchased, you’ll get this same ready-to-use BCG Matrix file instantly. It’s designed for clear strategic analysis and can be used for reporting, planning, or presentation.
What you see here is what you’ll download—fully intact and unchanged. The final document is delivered exactly as previewed, with no surprises.
Dogs
No named dog-class marketed product disclosed
Protalix BioTherapeutics does not show a clear dog-class branded product; its disclosed commercial assets are Elelyso and Elfabrio, while the rest of the portfolio is development-stage. As of the latest public disclosures through 2025, that means there is no obvious low-share, low-growth product sitting in a classic dog bucket. The portfolio looks more like a small commercial base plus pipeline than a weak legacy asset set.
0 divestiture candidates highlighted
Protalix BioTherapeutics, Inc. shows 0 divestiture candidates, and its public portfolio does not flag any brand for sale or shutdown. That matters because "dogs" are usually the assets firms try to exit. The latest public mix still centers on 2 marketed products, Elfabrio and Elelyso, plus 3 pipeline assets, so there is little sign of a formal dog unit.
2 commercial products, not a broad legacy line
Protalix BioTherapeutics, Inc. has just 2 commercial products, Elfabrio and Elelyso, so it is not carrying a broad legacy line with many aging low-return assets. That rare-disease focus makes the portfolio concentrated and riskier, but it also leaves fewer obvious “dog” candidates to prune. In BCG terms, the dog bucket is still limited because there is little product baggage to drain cash.
3 pipeline candidates are still the priority
PRX-110, PRX-115, and PRX-119 are still in development, so Protalix BioTherapeutics, Inc. is spending attention on future assets, not on a stagnant legacy line. That weakens a classic Dogs profile, which usually shows up in mature products with fading cash and little reinvestment. Protalix’s disclosed mix looks more like an early pipeline story than a dead-end asset.
- Three pipeline drugs remain the focus
- No clear mature cash cow cleanup case
- Dogs label fits poorly so far
No mature underperforming blockbuster tail
Protalix BioTherapeutics, Inc. shows no classic "dog" here: it has no disclosed mature blockbuster with heavy upkeep, and its model is centered on orphan biologics, not fading mass-market drugs. That cuts the risk of a big legacy product dragging returns. The real issue is pipeline execution, not brand decay.
No large, fading brand disclosed.
Orphan biologics limit legacy drag.
Main risk is pipeline uncertainty.
Protalix Has No Clear “Dogs” — Execution Is the Real Risk
Protalix BioTherapeutics, Inc. has no clear Dogs asset in its 2025 portfolio: it reports 2 marketed products, Elelyso and Elfabrio, plus 3 pipeline programs, PRX-110, PRX-115, and PRX-119. With 0 divestiture candidates and no disclosed fading legacy brand, the classic low-share, low-growth Dog bucket is weak here. The bigger issue is pipeline execution, not dead weight.
| Item | 2025 view |
|---|---|
| Marketed products | 2 |
| Pipeline programs | 3 |
| Divestiture candidates | 0 |
Question Marks
PRX-110, Phase IIa cystic fibrosis
PRX-110 finished Phase IIa, but it is still a development asset, not a commercial product. Cystic fibrosis affects about 100,000 people worldwide and around 40,000 in the U.S., so the market is meaningful, but PRX-110 has near-zero share because it is not sold yet. That fits a question mark: it needs more capital and progress, or it stays peripheral.
PRX-115, gout candidate
PRX-115 is still in development, so it has no sales or market share yet. Gout is a real commercial target, affecting about 9.2 million U.S. adults, but Protalix BioTherapeutics, Inc. has not proven demand capture for this asset. That makes PRX-115 a high-risk, high-upside Question Mark, with value tied to clinical wins and partner backing.
PRX-119, NETs-related diseases
PRX-119 has no approved sales as of end-2025, so its current market share is effectively 0. NETs-related diseases are still an early, growing niche, which gives PRX-119 upside if clinical data and regulation break right. That fits the classic question-mark profile: high potential, low current monetization.
Follow-on ProCellEx pipeline, undisclosed assets
Protalix BioTherapeutics, Inc.’s ProCellEx platform has already delivered a marketed product, but any undisclosed follow-on proteins still begin as low-share, high-uncertainty bets. With 2025 revenue still concentrated in a narrow product base, these assets need early R&D spend before they can turn into future stars.
Until Protalix BioTherapeutics, Inc. proves clinical data and partner demand, these programs stay question marks: high growth option, weak current share, and no clear cash flow yet.
- Low share, high risk
- Needs fresh pipeline wins
- Could become future stars
Fabry uptake beyond launch, still building share
PRX-102, sold as Elfabrio, is approved and commercial, but Fabry uptake still looks like a Question Mark because share is not yet locked in. In rare disease, the switch from entrenched enzyme therapy is slow, so adoption is still being tested rather than proven.
- Approved product, still early share build
- Rare-disease switching takes months, not weeks
- Growth is real, but not yet dominant
Protalix’s pipeline: big potential, but still no sales or market share
Protalix BioTherapeutics, Inc.’s question marks are PRX-110, PRX-115, and PRX-119: all are still unapproved, so 2025 sales are 0 and market share is effectively nil. They sit in real markets, including cystic fibrosis, gout, and NETs-linked disease, but each needs more clinical proof and funding before it can move past high-risk, high-upside status.
| Asset | 2025 Status | Market Share |
|---|---|---|
| PRX-110 | Phase IIa | 0% |
| PRX-115 | In development | 0% |
| PRX-119 | In development | 0% |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.